Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01221506 · ClinicalTrials.gov registry record · Early Phase 1
Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
A Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT01221506 is a Early Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 20 participants.
The verdict
NCT01221506, a Early Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
All patients who participate in this study will receive pazopanib. Pazopanib is an oral drug (pill) that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced kidney cancer. In this study, the investigators plan to learn more about the way this drug works by using special scans (MRIs and Ultrasounds) to help evaluate how this drug is working on this disease. Approximately 20 people with advanced kidney cancer will be enrolled on this study.
Interventions
- DRUG Pazopanib
- DEVICE DCE-MRI and Quantitative Doppler Ultrasound
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-10 |
| Est. Completion | 2019-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01221506
The ClinicalTrials.gov registry entry for NCT01221506 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pazopanib is the first listed.
NCT01221506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01221506 about?
NCT01221506 is a clinical study titled "Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)". All patients who participate in this study will receive pazopanib. Pazopanib is an oral drug (pill) that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced kidney cancer. In this study, the investigators plan to learn more about the way this drug works by ...
What is the current status of trial NCT01221506?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2010-10. Estimated completion is 2019-04.
What interventions are being tested in trial NCT01221506?
The interventions under investigation include: Pazopanib (DRUG), DCE-MRI and Quantitative Doppler Ultrasound (DEVICE).
Who is sponsoring clinical trial NCT01221506?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.